Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.

Ede NJ, Good AJ, Tobias J, Garner-Spitzer E, Zielinski CC, Wiedermann U

Open source

DOI
10.3389/fonc.2022.939356
Published
2022
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2022.939356,
  title = {Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.},
  author = {Ede NJ and Good AJ and Tobias J and Garner-Spitzer E and Zielinski CC and Wiedermann U},
  year = {2022},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2022.939356},
  url = {https://doi.org/10.3389/fonc.2022.939356}
}

RIS

TY  - JOUR
TI  - Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.
AU  - Ede NJ
AU  - Good AJ
AU  - Tobias J
AU  - Garner-Spitzer E
AU  - Zielinski CC
AU  - Wiedermann U
PY  - 2022
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2022.939356
UR  - https://doi.org/10.3389/fonc.2022.939356
ER  - 

APA

NJ, E., AJ, G., J, T., E, G., CC, Z., & U, W. (2022). Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.. Frontiers in oncology. https://doi.org/10.3389/fonc.2022.939356

Source records